Ernest Cheung1, Mehrdad Nikfarjam1, Louise Jackett2, Damien M Bolton1,3, Joseph Ischia1,3, Oneel Patel1. 1. Department of Surgery, The University of Melbourne, Victoria, Australia. 2. Department of Anatomical Pathology, Austin Health, Heidelberg, Victoria, Australia. 3. Department of Urology, Austin Health, Heidelberg, Victoria, Australia.
Abstract
BACKGROUND: Ischaemia-reperfusion injury (IRI) is a major obstacle during liver transplantation and resection surgeries for cancer, with a need for effective and safe drugs to reduce IRI. Zinc preconditioning has been shown to protect against liver IRI in a partial (70%) ischaemia model. However, its efficacy against a clinically relevant Pringle manoeuvre that results in global liver ischaemia (100%) is unknown. AIMS: The aim of this study was to test the efficacy of zinc preconditioning in a rat model of global liver ischaemia. METHODS: Rats were preconditioned via subcutaneous injection of 10 mg/kg of ZnCl2, 24 h and 4 h before ischaemia. Total liver ischaemia (100%) was induced by placing a clamp across the portal triad for 30 min. Liver injury was assessed by serum alanine transaminase (ALT) and aspartate transaminase (AST) levels in blood taken before ischaemia (baseline) and at 1, 2, 4, 24, 48, 72, 96 and 120 hours after ischaemia. Animals were culled after 7 days, and the harvested livers were histologically analysed. RESULTS: On a two-way repeated-measures analysis of variance, there was a statistically significant (p = 0.025) difference in the mean ALT levels between saline- and ZnCl2-treated groups. Specifically at 24 h after ischaemia, the ALT (341 ± 99 U/L) and AST (606 ± 78 U/L) in the zinc-treated group were significantly less than the ALT (2863 ± 828 U/L) and AST (3591 ± 948 U/L) values in the saline-treated group. Zinc significantly reduced neutrophil infiltration and necrosis compared with the saline control. CONCLUSION: Zinc preconditioning reduces the overall hepatocellular damage from IRI. These results lay the foundation to assess the benefit of zinc preconditioning for clinical applications.
BACKGROUND: Ischaemia-reperfusion injury (IRI) is a major obstacle during liver transplantation and resection surgeries for cancer, with a need for effective and safe drugs to reduce IRI. Zinc preconditioning has been shown to protect against liver IRI in a partial (70%) ischaemia model. However, its efficacy against a clinically relevant Pringle manoeuvre that results in global liver ischaemia (100%) is unknown. AIMS: The aim of this study was to test the efficacy of zinc preconditioning in a rat model of global liver ischaemia. METHODS: Rats were preconditioned via subcutaneous injection of 10 mg/kg of ZnCl2, 24 h and 4 h before ischaemia. Total liver ischaemia (100%) was induced by placing a clamp across the portal triad for 30 min. Liver injury was assessed by serum alanine transaminase (ALT) and aspartate transaminase (AST) levels in blood taken before ischaemia (baseline) and at 1, 2, 4, 24, 48, 72, 96 and 120 hours after ischaemia. Animals were culled after 7 days, and the harvested livers were histologically analysed. RESULTS: On a two-way repeated-measures analysis of variance, there was a statistically significant (p = 0.025) difference in the mean ALT levels between saline- and ZnCl2-treated groups. Specifically at 24 h after ischaemia, the ALT (341 ± 99 U/L) and AST (606 ± 78 U/L) in the zinc-treated group were significantly less than the ALT (2863 ± 828 U/L) and AST (3591 ± 948 U/L) values in the saline-treated group. Zinc significantly reduced neutrophil infiltration and necrosis compared with the saline control. CONCLUSION: Zinc preconditioning reduces the overall hepatocellular damage from IRI. These results lay the foundation to assess the benefit of zinc preconditioning for clinical applications.
Authors: Pim B Olthof; Rowan F van Golen; Ben Meijer; Adriaan A van Beek; Roelof J Bennink; Joanne Verheij; Thomas M van Gulik; Michal Heger Journal: Biochim Biophys Acta Mol Basis Dis Date: 2016-10-27 Impact factor: 5.187
Authors: Marta Massip-Salcedo; M Amine Zaouali; Susagna Padrissa-Altés; Arani Casillas-Ramirez; Joan Rodés; Joan Roselló-Catafau; Carmen Peralta Journal: Hepatology Date: 2008-02 Impact factor: 17.425
Authors: Matthew P Brennan; Albert J Sinusas; Tamas L Horvath; J G Collins; Martha J Harding Journal: Lab Anim (NY) Date: 2009-03 Impact factor: 12.625
Authors: Luciana T Kato; Renato S Poggetti; Belchor Fontes; Paulo C B Massarollo; Riad N Younes; Ana Maria de L C Heimbecker; Dario Birolini Journal: Acta Cir Bras Date: 2007 Jul-Aug Impact factor: 1.388
Authors: Marlon Perera; John El Khoury; Vidyasagar Chinni; Damien Bolton; Liang Qu; Paul Johnson; Jason Trubiano; Christine F McDonald; Daryl Jones; Rinaldo Bellomo; Oneel Patel; Joseph Ischia Journal: BMJ Open Date: 2020-12-02 Impact factor: 2.692